1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:41 am EDT
79.10 SEK   +0.89%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

XBRANE HAS INITIATED DEVELOPMENT OF TWO NEW BIOSIMILAR CANDIDATES, BUILDING AN ONCOLOGY BIOSIMILAR PORTFOLIO TARGETING EUR23 BILLION IN ANNUAL REFERENCE PRODUCT SALES

12/14/2021 | 09:17am EDT

Xbrane Biopharma AB (publ) ('Xbrane' eller 'Bolaget') (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced the initiation of developing two new biosimilar candidates referencing Keytruda and Darzalex respectively.

Together with the continued development of Xdivane, a biosimilar candidate referencing Opdivo, this forms an oncology biosimilar portfolio addressing EUR23 billion of combined annual reference product sales. Due to the announcement, Xbrane will host a videoconference tomorrow Tuesday December 14th, 11.00-11.45, registration in the link below.

At the capital markets day held on May 17, 2021, Xbrane announced its ambition to start developing at least one new biosimilar candidate per year. Following a thorough strategic portfolio review and preparatory work during the fall of 2021, Xbrane's board of directors decided to initiate the development of biosimilar candidates referencing Keytruda and Darzalex.

Keytruda is a PD1 inhibitor used in oncology treatment with annual sales of EUR13 billion. Darzalex is a CD38 inhibitor used in the treatment of Multiple Myeloma with annual sales of EUR3.8 billion. Together with Xdivane, these new biosimilar candidates form an oncology biosimilar portfolio targeting EUR23 billion combined in annual reference product sales, which could be launched in 2028-2029 when the respective patents expire.

With the development of Xdivane, Xbrane has expanded its high-yield protein expression platform into mammalian cells, resulting in five recently approved patents. Xbrane will leverage this platform for the upcoming programs with the aim of getting the lowest production costs amongst competing biosimilars on the market.

'With our high-yield platform technology, experienced team, and recently established development lab, we believe we are well positioned to accelerate the development of our portfolio. The development of this oncology biosimilar portfolio poses a real opportunity for us to make a sizable difference and to improve the accessibility of critical oncology products for millions of patients world-wide,' says Martin Amark, CEO of Xbrane

Contact:

Martin Amark

Tel: +46 76 309 37 77

Email: martin.amark@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis biosimilar candidate, addresses the EUR 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane is expected for the second half of 2022. Xbrane has additionally two biosimilar candidates in its pipeline targeting EUR 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.

This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-13 20:00 CET.

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
More news
Financials
Sales 2021 18,7 M 1,89 M 1,89 M
Net income 2021 -225 M -22,7 M -22,7 M
Net cash 2021 445 M 44,9 M 44,9 M
P/E ratio 2021 -7,98x
Yield 2021 -
Capitalization 1 963 M 198 M 198 M
EV / Sales 2021 81,1x
EV / Sales 2022 5,66x
Nbr of Employees 64
Free-Float 66,3%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 78,40 SEK
Average target price 235,00 SEK
Spread / Average Target 200%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-25.19%198
MODERNA, INC.-43.55%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.50%38 185
SEAGEN INC.-7.74%26 255
ICON PUBLIC LIMITED COMPANY-30.82%17 418